Drooling OCD is actually not a medical term, but a form of OCD from a professional point of view, so the drugs with anti-compulsive effects are selective 5-hydroxytryptamine reuptake inhibitors, which are tricyclic antidepressants of the SSRI class. Among them, selective 5-hydroxytryptamine reuptake inhibitors are currently the first-line drugs for the treatment of OCD, that is, the drugs of choice. Tricyclic antidepressants, such as clomipramine, are now used less often in clinical practice because of their more severe side effects. Pharmacological treatment includes three treatment phases: acute phase, consolidation phase and maintenance phase. The aim of treatment in the acute phase of drooling OCD is to relieve symptoms and restore social functioning. Medications are generally chosen from first-line drugs, that is, selective 5-hydroxytryptamine reuptake inhibitors, such as fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram. The dose of the drug should be adequate, and these drugs often require the higher or highest dose recommended by the prescription. Most patients show significant improvement after 4-6 weeks of treatment with adequate or higher doses, while some patients take 10-12 weeks to show improvement. In addition, the combination of antipsychotics on top of SSRI-based treatment can increase the effectiveness of anti-compulsive treatment. Commonly used are atypical antipsychotics, such as risperidone, aripiprazole, quetiapine, and olanzapine. Patients who are well treated in the acute phase can enter a 1-2 year consolidation and maintenance phase of treatment, which is aimed at reducing relapse. The medication used in both phases is generally the same as in the acute phase. Patients treated in the maintenance phase, if their condition has been relatively stable, can be considered to gradually reduce the medication until it is discontinued after systematic evaluation by a specialist.